Total Valuation
GlaxoSmithKline has a market cap or net worth of €90.43B. The enterprise value is €125.93K.
Market Cap€90.43B
Enterprise Value€125.93K
Share Statistics
GlaxoSmithKline has 2,022,697,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,022,697,600
Owned by Insiders―
Owned by Institutions1.15%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 16.61%.
Return on Equity (ROE)0.35
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)16.61%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee488.73K
Profits Per Employee83.64K
Employee Count66,841
Asset Turnover0.54
Inventory Turnover1.52
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 16.1. GlaxoSmithKline’s PEG ratio is 0.10.
PE Ratio16.1
PS Ratio2.26
PB Ratio4.51
Price to Fair Value4.51
Price to FCF12.66
Price to Operating Cash Flow9.61
PEG Ratio0.10
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 2.82.
Revenue32.67B
Gross Profit23.65B
Operating Income8.34B
Pretax Income7.40B
Net Income5.72B
EBITDA10.40B
Earnings Per Share (EPS)2.82
Cash Flow
In the last 12 months, operating cash flow was 8.74B and capital expenditures -1.76B, giving a free cash flow of 6.98B billion.
Operating Cash Flow8.74B
Free Cash Flow6.98B
Free Cash Flow per Share3.45
Dividends & Yields
GlaxoSmithKline pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.55
52-Week Price Change44.59%
50-Day Moving Average44.46
200-Day Moving Average43.57
Relative Strength Index (RSI)49.86
Average Volume (3m)21.00
Important Dates
GlaxoSmithKline upcoming earnings date is Oct 28, 2026, Before Open (Confirmed).
Last Earnings DateJul 28, 2026
Next Earnings DateOct 28, 2026
Ex-Dividend Date―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 103.36%
Current Ratio0.82
Quick Ratio0.54
Debt to Market Cap0.24
Net Debt to EBITDA1.37
Interest Coverage Ratio12.14
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
Income Tax1.11B
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 8.46, with an EV/FCF ratio of 15.11.
EV to Sales2.69
EV to EBITDA8.46
EV to Free Cash Flow15.11
EV to Operating Cash Flow12.32
Balance Sheet
GlaxoSmithKline has €3.09B in cash and marketable securities with €18.13B in debt, giving a net cash position of -€15.04B billion.
Cash & Marketable Securities€3.09B
Total Debt€18.13B
Net Cash-€15.04B
Net Cash Per Share-€7.44
Tangible Book Value Per Share-€3.82
Margins
Gross margin is 73.29%, with operating margin of 25.52%, and net profit margin of 17.50%.
Gross Margin73.29%
Operating Margin25.52%
Pretax Margin22.66%
Net Profit Margin17.50%
EBITDA Margin31.84%
EBIT Margin24.76%
Analyst Forecast
The average price target for GlaxoSmithKline is €59.44, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€59.44
Price Target Upside31.51% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast1.52%
EPS Growth Forecast38.08%